Laboratory of Genomics and Transcriptomics
Glioblastoma is a human primary brain tumor characterized by a poor survival and limited treatment options. Despite the latest advances in surgery, radiological assessment, and radiotherapy treatment, the incidence of glioblastoma is roughly comparable to that of mortality, and the prognosis is almost always related to intracranial progression after surgery and radio-chemotherapy.
Sara Franceschi is involved in understanding aspects regarding both etiology and progression of the disease at a molecular level. She strengthen her knowledge in brain cancer biology working several months at the Memorial Sloan-Kettering Cancer Center of New York.
The molecular evolution of tumors based on their clonal heterogeneity and the correlation between molecular alterations and different morphology of tumors are investigated by a laser capture microdissection approach, followed by nucleic acids extraction and NGS analysis.
Sara Franceschi is also interested in understanding the molecular alterations at the base of the differences in different survival of patients affected by tumors of the same histological grade, performing cell functional studies to confirm the biological effect of her findings.
Sara Franceschi received her Master’s degree in Pharmaceutical Chemistry and Technology and her PhD in Molecular and Experimental Oncology at the University of Pisa, Italy.